Author: Press Room

Watch full video on YouTube

Watch full video on YouTube

One of my favorite duties as the leader of our Seeking Alpha Investing Group is answering questions from members and providing analysis of their prospective trades or tickers. Recently, one of the members inquired about X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) and why the ticker was selling off following they publicized mixed interim data from mavorixafor’s Phase II study for chronic neutropenia (CN). The data revealed that 3 out of 23 patients on Mavorixafor discontinued due to non-serious adverse events, which resulted in the share price being nearly cut in half and has failed to show any signs of a recovery. Although…

Unlock the US Election Countdown newsletter for freeThe stories that matter on money and politics in the race for the White HouseJoe Biden is facing renewed pressure to end his re-election bid, after a Democratic lawmaker called on him to drop out of the presidential race and state governors sought a White House meeting to discuss his candidacy.Lloyd Doggett, a Democratic congressman from Texas, on Tuesday became the first lawmaker from the president’s party to publicly call for Biden to step aside, saying “too much is at stake to risk a [Donald] Trump victory” in November’s election. “Recognising that, unlike…

Estate planning sometimes addresses the special needs of lesbian, gay, bisexual, transgender, and queer (LGBTQ+) people, or those who have family members in the LGBTQ+ community. Statistics demonstrate the reality that the number of people undertaking estate planning for whom LGBTQ+ considerations should be incorporated is growing. This article will provide an overview of some of the many planning and document considerations. This will include an explanation of a novel technique that may prove helpful for some LGBTQ+ people, especially given some of the changing tides in attitudes and law. There are risks that federal policies that prohibit discrimination on…

Our goal here at Credible Operations, Inc., NMLS Number 1681276, referred to as “Credible” below, is to give you the tools and confidence you need to improve your finances. Although we do promote products from our partner lenders who compensate us for our services, all opinions are our own. The interest rate on a 30-year fixed-rate mortgage is 7.125% as of May 30, which is 0.135 percentage points higher than yesterday. Additionally, the interest rate on a 15-year fixed-rate mortgage is 6.375%, which is 0.250 percentage points higher than yesterday.  With mortgage rates changing daily, it’s a good idea to…

Student loan debt is a hot topic this election season. As the battle for and against debt forgiveness rages on, many borrowers are being vocal about their opinions on forgiveness. Less than a third of the American public currently approves of how student loan debt is being handled by the Biden Administration, a poll from the University of Chicago showed.  Many adults do believe forgiveness is necessary in certain circumstances, however. In those instances, borrowers along all party lines support the Biden Administration’s efforts to reduce student loan debt.”In recent years, more than a million borrowers who were defrauded by…

Watch full video on YouTube

Watch full video on YouTube

Candel Therapeutics, Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company developing biological immunotherapies for several types of cancer. CADL’s treatments combine anti-tumor elements with immune-stimulatory components, improving the immune system’s targeting of malignant cells. CADL uses proprietary technology to target and destroy cancer cells while stimulating an immune response. The company’s enLIGHTEN Discovery platform leverages herpes simplex viruses [HSV] to create new multimodal immunotherapy candidates for solid tumors rapidly. This means CADL also integrates artificial intelligence-driven cytotoxic components with programmable vectors. Its pipeline comprises CAN-2409 and CAN-3110, yielding promising trial results to date. Unfortunately, valuation and financial constraints supersede my optimism…